Evaxion partners with pharmaceutical company afrigen biologics to develop novel mrna vaccine against gonorrhea

Copenhagen, denmark, sept. 20, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, today announced a collaboration with afrigen biologics (afrigen). the collaboration aims at developing a prophylactic vaccine based on evaxion's eden™-discovered gonorrhea targets.
EVAX Ratings Summary
EVAX Quant Ranking